JP2016525136A5 - - Google Patents

Download PDF

Info

Publication number
JP2016525136A5
JP2016525136A5 JP2016528481A JP2016528481A JP2016525136A5 JP 2016525136 A5 JP2016525136 A5 JP 2016525136A5 JP 2016528481 A JP2016528481 A JP 2016528481A JP 2016528481 A JP2016528481 A JP 2016528481A JP 2016525136 A5 JP2016525136 A5 JP 2016525136A5
Authority
JP
Japan
Prior art keywords
formula
represents hydrogen
methyl
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016528481A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016525136A (ja
JP6410819B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/065608 external-priority patent/WO2015011087A1/de
Publication of JP2016525136A publication Critical patent/JP2016525136A/ja
Publication of JP2016525136A5 publication Critical patent/JP2016525136A5/ja
Application granted granted Critical
Publication of JP6410819B2 publication Critical patent/JP6410819B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016528481A 2013-07-23 2014-07-21 置換オキソピリジン誘導体および第XIa因子/血漿としてのその使用 Expired - Fee Related JP6410819B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13177605 2013-07-23
EP13177605.6 2013-07-23
PCT/EP2014/065608 WO2015011087A1 (de) 2013-07-23 2014-07-21 Substituierte oxopyridin-derivate und ihre verwendung als faktor xia / plasma

Publications (3)

Publication Number Publication Date
JP2016525136A JP2016525136A (ja) 2016-08-22
JP2016525136A5 true JP2016525136A5 (https=) 2017-08-17
JP6410819B2 JP6410819B2 (ja) 2018-10-24

Family

ID=48803476

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016528481A Expired - Fee Related JP6410819B2 (ja) 2013-07-23 2014-07-21 置換オキソピリジン誘導体および第XIa因子/血漿としてのその使用

Country Status (7)

Country Link
US (2) US9475809B2 (https=)
EP (1) EP3024822B1 (https=)
JP (1) JP6410819B2 (https=)
CN (1) CN105555767B (https=)
CA (1) CA2918814C (https=)
ES (1) ES2633248T3 (https=)
WO (1) WO2015011087A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2712699T3 (es) 2013-03-25 2019-05-14 Bristol Myers Squibb Co Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa
CA2918814C (en) * 2013-07-23 2021-10-12 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives and use thereof as factor xia/plasma
NO2760821T3 (https=) 2014-01-31 2018-03-10
CN116987080A (zh) 2014-01-31 2023-11-03 百时美施贵宝公司 作为因子xia抑制剂的具有杂环p2′基团的大环化合物
CN107074821B (zh) 2014-09-04 2020-05-22 百时美施贵宝公司 为fxia抑制剂的二酰胺大环化合物
WO2016046156A1 (de) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
ES2722425T3 (es) 2014-09-24 2019-08-12 Bayer Pharma AG (2H)-2-Oxopiridinas como inhibidores del factor XIa para el tratamiento de enfermedades trombóticas
ES2716417T3 (es) 2014-09-24 2019-06-12 Bayer Pharma AG Derivados de oxopiridina sustituidos con acción antiinflamatoria y antitrombótica
US10077265B2 (en) 2014-09-24 2018-09-18 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
US10138236B2 (en) 2014-09-24 2018-11-27 Bayer Pharma Aktiengesellschaft Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
EP3344618A1 (de) 2015-09-04 2018-07-11 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
WO2017074833A1 (en) 2015-10-29 2017-05-04 Merck Sharp & Dohme Corp. Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use
EP3500556B1 (en) 2016-08-22 2023-08-02 Merck Sharp & Dohme LLC Pyridine-1-oxide derivatives and their use as factor xia inhibitors
CN106831761B (zh) * 2016-12-14 2019-02-12 浙江工业大学 顺式四氢-1H-吡咯并[3,4-b]吡啶-2,5(3H,6H)-二酮的合成方法
PE20210165A1 (es) 2018-04-10 2021-01-26 Bayer Pharma AG Un derivado de oxopiridina sustituido
CR20210342A (es) 2018-12-21 2021-08-09 Bayer Ag Derivados de oxopiridina sustituidos
US20220144848A1 (en) 2018-12-21 2022-05-12 Bayer Aktiengesellschaft Substituted oxopyridine derivatives
CN110105276A (zh) * 2019-06-24 2019-08-09 红河学院 一种2-喹啉酮化合物及其制备方法
CN112778273B (zh) * 2019-11-11 2022-08-23 江西济民可信集团有限公司 环酮并吡啶酮类化合物及其制备方法和用途
CN112778277B (zh) * 2019-11-11 2024-04-02 江西济民可信集团有限公司 环酮并吡啶酮联杂芳环化合物及其制备方法和用途
CN113135930B (zh) * 2020-01-17 2023-11-17 上海济煜医药科技有限公司 呋喃并吡啶酮咪唑化合物及其制备方法和用途
CN113135929B (zh) * 2020-01-17 2024-04-19 江西济民可信集团有限公司 呋喃并吡啶酮酰胺化合物及其制备方法和用途
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0407342A3 (en) * 1989-07-06 1991-07-10 Ciba-Geigy Ag Pyrimidine derivatives
RS56037B1 (sr) * 2004-06-24 2017-09-29 Vertex Pharma Modulatori atp-vezujućih kasetnih transportera
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006076575A2 (en) * 2005-01-13 2006-07-20 Bristol-Myers Squibb Company Substituted biaryl compounds as factor xia inhibitors
ES2365815T3 (es) * 2005-12-14 2011-10-11 Bristol-Myers Squibb Company Análogos de arilpropionamida, arilacrilamida, arilpropinamida o arilmetilurea como inhibidores del factor xia.
CN101605779B (zh) * 2006-12-15 2013-11-20 百时美施贵宝公司 作为凝血因子xia抑制剂的芳基丙酰胺、芳基丙烯酰胺、芳基丙炔酰胺或芳基甲基脲类似物
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
CN101970433A (zh) * 2007-12-11 2011-02-09 先灵公司 γ分泌酶调节剂
US8268820B2 (en) * 2009-03-26 2012-09-18 Hoffmann-La Roche Inc. 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds
EP2625170A1 (en) * 2010-10-07 2013-08-14 Takeda Pharmaceutical Company Limited 1,4-oxazepane derivatives
RU2630677C2 (ru) * 2011-12-21 2017-09-12 Оно Фармасьютикал Ко., Лтд. Соединения
CA2918814C (en) * 2013-07-23 2021-10-12 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives and use thereof as factor xia/plasma

Similar Documents

Publication Publication Date Title
JP2016525136A5 (https=)
JP2016515562A5 (https=)
JP2018519323A5 (https=)
JP2016535031A5 (https=)
JP2016540742A5 (https=)
JP2016507581A5 (https=)
JP2015500843A5 (https=)
JP2019524883A5 (https=)
JP2016516043A5 (https=)
JP2013542261A5 (https=)
JP2019522055A5 (https=)
CA2749048A1 (en) Benzimidazole and pyrazolopyridine derivatives for treating and/or preventing cardiovascular diseases
JP2011528658A5 (https=)
JP2015531773A5 (https=)
JP2018514518A5 (https=)
JP2009515988A5 (https=)
AR102487A1 (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
JP2014525420A5 (https=)
JP2017509689A5 (https=)
JP2016525075A5 (https=)
JP2016513696A5 (https=)
JP2017528496A5 (https=)
JP2017506666A5 (https=)
JP2015516000A5 (https=)
JP2013540712A5 (https=)